8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 29, 2015)

Filed January 29, 2015For Securities:ABT

Summary

This 8-K filing by Abbott Laboratories (ABT) on January 29, 2015, primarily announces the company's financial results for the fourth quarter and full year 2014. The report highlights the use of non-GAAP financial measures to provide a clearer view of ongoing operational performance, adjusting for items like cost reduction initiatives, integration/separation costs, and tax-related adjustments. Investors are encouraged to consider these non-GAAP figures alongside traditional GAAP measures for a comprehensive understanding of the company's financial health and operational trends. While specific financial figures are not detailed within the 8-K itself but are referenced via an attached press release (Exhibit 99.1), the core message is Abbott's approach to reporting performance. Management believes these adjusted metrics offer valuable insights into the underlying business, excluding the impact of unusual or one-time events that might otherwise obscure underlying trends. This reporting practice is designed to aid investors in evaluating the company's sustained performance.

Key Highlights

  • 1Abbott Laboratories announced its Q4 and Full Year 2014 financial results on January 29, 2015.
  • 2The company is utilizing non-GAAP financial measures in its reporting.
  • 3Non-GAAP measures are adjusted to exclude specific items such as cost reduction initiatives, integration/separation costs, and transaction-related costs.
  • 4Tax adjustments related to a one-time repatriation of ex-U.S. earnings and resolution of tax uncertainties are also excluded from non-GAAP reporting.
  • 5Intangible amortization expense is excluded from non-GAAP measures to enhance visibility into core operations.
  • 6Abbott's management believes these non-GAAP measures provide a better evaluation of ongoing business performance.
  • 7The full financial results are detailed in a press release furnished as Exhibit 99.1 to the 8-K filing.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce Abbott Laboratories' financial results for the fourth quarter and the full fiscal year 2014. It also informs investors about the company's use of non-GAAP financial measures in reporting these results.

Abbott's non-GAAP financial measures adjust for unusual or unpredictable items. These include cost reduction initiatives, integration and separation-related costs, transaction-related costs, a philanthropic contribution, benefits from U.S. tax law changes, tax expenses from one-time repatriation of ex-U.S. earnings, and tax adjustments for resolving prior year tax uncertainties. Intangible amortization expense is also excluded.

Abbott's management believes that presenting non-GAAP financial measures provides useful information to investors by allowing them to better evaluate ongoing business performance. These measures help to exclude the impact of specific costs or events that are not considered part of the company's core, recurring operations, thus offering a clearer view of the underlying business trends.

The detailed financial results for the fourth quarter and full year 2014 are provided in a press release issued by Abbott Laboratories. This press release is furnished as Exhibit 99.1 to this 8-K filing and is incorporated herein by reference.